20 July 2022 - With NHS England highlighting savings of £1.2 billion on medicines in three years coming from both deals on generics and new innovative treatments, Leela Barham takes stock of what we know about the impact on spending.

As industry raises concerns about the multiple ways spend is managed – unsaid but pointing to a big squeeze on drug spending – she argues that industry will need to put together a strong evidence-based case to achieve change.

Read Pharmaphorum article